Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.62 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.62 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30824506 | 1.00 | CYSLTR1 (0.62) | CYSLTR1CYSLTR2PDE10AGPBAR1CYP1A2 | |
| SCHEMBL2353460 | 0.83 | CYSLTR1 (0.67) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL18546229 | 0.81 | FFAR1 (0.48) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL4268808 | 0.81 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2PDE10AGPBAR1CYP1A2 | |
| SCHEMBL1262903 | 0.80 | CYSLTR1 (0.62) | CYSLTR1CYSLTR2PDE10AGPBAR1CYP1A2 | |
| SCHEMBL1715309 | 0.80 | CYSLTR1 (0.62) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL13314537 | 0.79 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2PDE10AGPBAR1CYP1A2 | |
| SCHEMBL12530278 | 0.79 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2PDE10AGPBAR1CYP1A2 | |
| SCHEMBL10547475 | 0.79 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL7509236 | 0.78 | CYSLTR1 (0.62) | CYSLTR1CYSLTR2PDE10AGPBAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025862-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2024006881-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023205778-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4230620-A1 | SUBSTITUTED N-AMINO-N-BENZOIC ACID URACILS, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230621-A1 | SUBSTITUTED N-BENZOIC ACID URACILS, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer AG (DE) | 2023-08-23 | — | — | EP | disclosed |
| WO-2021013800-A1 | SUBSTITUTED N-PHENYL-N-AMINOUARCILS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021013799-A1 | SUBSTITUTED N-PHENYL URACILS, SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | WO | disclosed |
| CN-106232572-B | The manufacturing method of nitro compound | 住友化学株式会社 | 2018-11-13 | — | — | CN | disclosed |
| CN-105399599-B | A kind of method for preparing hexachlorobutadiene | 浙江工业大学 | 2018-05-29 | — | — | CN | disclosed |
| CN-106164041-B | The manufacture method of nitro compound | 住友化学株式会社 | 2018-05-04 | — | — | CN | disclosed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089380-A2 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089471-A2 | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089896-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
| US-4252945-A | 4(1H)-QUINOLONES REACTED WITH HYDRAZINE TO FORM 5-(2-AMINOPHENYL)PYRAZOLES WHICH ARE CYCLIZED WITH PHOSGENE, THIOPHOSGENE OR ETHYL CHLOROFORMATE | E. R. SQUIBB & SONS, INC. (US) | 1981-02-24 | — | — | US | disclosed |
| US-4166862-A | WEIGHT-GAIN PROMOTERS | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1979-09-04 | — | — | US | disclosed |
| US-4163746-A | ANABOLIC, 5-METHYL-7-ALKOXYISOFLAVONES | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1979-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025862-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | PFAS, DDT, NOTUM | CYSLTR1 3539/4885CYSLTR2 3784/4885PDE10A 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.